Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
ONCOLOGY RESEARCH AND TREATMENT（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要